|
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials Clinical research trials and A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials. A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials clinical trial. Participants oftentimes recieve the most expert healthcare available for their A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials  A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to find out more about how persons respond to HIV-1 infection if they have received an experimental HIV-1 vaccine before they became HIV-infected. It is important to study people who have been given experimental HIV vaccines and who later became HIV-infected for several reasons. First, if HIV infection is found and then cleared, it is important to note the relationship between the virus and the vaccine. This may give an understanding of the immunity. A second reason is to better understand the immune response in those who received a vaccine compared to those who received placebo (no vaccine). If the vaccine does not prevent HIV infection, it will be important to study the progression of the disease. Understanding the immune response in vaccinated patients after infection and the impact on symptoms and disease progression may give valuable information for future vaccine trials and the effectiveness of HIV vaccines.
Details: It is important to study persons vaccinated with candidate HIV-1 vaccines who have become HIV-1 infected for the following reasons. First, if transient HIV-1 infection is detected and then is effectively suppressed or cleared, it will be important to document the antigenic relationship between the breakthrough virus and the vaccine epitopes to attempt to answer questions about the specificity and breadth of the immune response and the determinants of immunity. A second reason is to gain a better understanding of vaccine-induced responses in those participants who are transiently or persistently HIV-1-infected compared to placebo recipients who become HIV-1-infected. If the vaccine does not prevent HIV-1 infection, it will be important to characterize the course of the disease as measured by longitudinal viral load measurements, CD4+ counts, and clinical symptoms. Understanding the breadth, magnitude, and specificity of the immune response in partially or fully immunized vaccinees after infection and the impact on clinical symptoms and disease progression can potentially result in valuable information for the subsequent design of vaccine efficacy trials and, ultimately, in consideration of potential effectiveness of HIV-1 vaccines. Study visits occur at Days 0, 7, 14, 28, then at 2 months, 3 months, 6 months, and every 6 months thereafter. At these visits, patients are given a physical exam, blood is drawn, and a donation of genital fluids is requested at certain visits. Patients are asked to donate samples of either semen (men) or cervical secretions (women); viral load is measured and compared to the amount and types of virus in the blood. He/she may refuse to donate these genital fluids and still be eligible to remain in the study. Primary medical care or medications for HIV infection are not provided by this study.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Participated in HVTN, AVEG, HIVNET Phase I or Phase II vaccine trials or HIV vaccine preparedness trial HVTN 903 and became HIV infected after study enrollment. - Are able and willing to provide information so that they may be located. Exclusion Criteria Patients may not be eligible for this study if they: - Have a medical or mental problem that, in the opinion of the investigator, would interfere with the study.
Total Enrollment: 56
Location and Contact Information:
Overall Study Official:
ConnieCelum, Study Chair,
Vanderbilt Univ Hosp *Recruiting*
Nashville, Tennessee, 3723-2582
United States
Recruiting Kyle Rybczyk 615-322-5641
San Francisco Dept of Hlth / AIDS Office *Recruiting*
San Francisco, California, 94102
United States
Recruiting Rose Quinones 415-544-9014
Columbia Univ *Recruiting*
New York City, New York, 10032
United States
Recruiting Scott Hammer 212-305-7185
Univ of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Susan Duncan 205-975-2840
Fred Hutchinson Cancer Research Ctr *Recruiting*
Seattle, Washington, 98109
United States
Recruiting Julie McElrath 206-667-6704
New York Blood Ctr / Union Square *Recruiting*
New York City, New York, 10003
United States
Recruiting Kent Curtis 212-388-0008
Mt Zion Hospital *Recruiting*
San Francisco, California, 94102
United States
Recruiting Rose Quinones 415-544-9014
JHU-CIR/DC *Recruiting*
Baltimore, Maryland, 21205
United States
Recruiting Eric Zimmerman 410-955-7283
Fenway Community Health *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Lorrain Schieve 617-927-6075
Johns Hopkins Univ *Recruiting*
Baltimore, Maryland, 21205
United States
Recruiting Eric Zimmerman 410-955-7283
Harvard University / Brigham and Women's Hospital *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting John Abbatematteo 617-732-5996
Miriam Hosp *Recruiting*
Providence, Rhode Island, 02906
United States
Recruiting Gail Yates 401-793-4335
Univ of Rochester Med Ctr *Recruiting*
Rochester, New York, 14642
United States
Recruiting Catherine Bunce 585-275-5744
Saint Louis University School of Medicine *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Robert Belshe 314-577-8648
Additional Information:
Study ID Numbers: HVTN 403;
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029913
Other Hiv Infections Studies:
1. A Study of Patients with AIDS Syndrome
2. The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients
3. A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
4. The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
5. Safety of the Candidate Vaccine C4-V3 Alone or with Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
|
|
|
|
|
|
|
|
